Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02497131
Recruitment Status : Recruiting
First Posted : July 14, 2015
Last Update Posted : February 10, 2020
Sponsor:
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS

Brief Summary:
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of Brentuximab Vedotin (BV) as a single agent in relapsed/refractory CD30+ PTCL patients.

Condition or disease Intervention/treatment Phase
Lymphatic Diseases Drug: Brentuximab Vedotin Phase 2

Detailed Description:

BV will be administered as a single IV infusion on Day 1 of each 21-day cycle. Measures of anti-cancer activity will be assessed using the revised response criteria for malignant lymphoma (Cheson et al. 2007).

Computed tomography (CT) scans (chest, neck, abdomen, and pelvis) and PET scan will be performed at baseline and Cycles 3, 8, 12, and 16. Patients will have an End of Treatment (EOT) assessment 30 ± 7 days after receiving their final dose of study drug. Patients with at least stable disease will enter short follow up phase till month 24 with radiology assessment every 6 months and visit every 12 weeks. After month 24 and for all patients with progressive disease, long-term follow-up assessments (including survival, disease status and next therapy information) will be performed every 12 weeks until either patient death or study closure, whichever occurs first.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Actual Study Start Date : September 21, 2015
Actual Primary Completion Date : September 24, 2019
Estimated Study Completion Date : December 2021


Arm Intervention/treatment
Experimental: Brentuximab Vedotin 16 cycles
Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
Drug: Brentuximab Vedotin
Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
Other Name: SGN35




Primary Outcome Measures :
  1. overall objective response rate (ORR) [ Time Frame: 1 year ]
    Overall objective response rate (ORR) is defined as the proportion of patients with complete remission (CR) or partial remission (PR) according to the Revised Response Criteria for Malignant Lymphoma


Secondary Outcome Measures :
  1. Duration of response [ Time Frame: 1 year ]
    Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to lymphoma

  2. Complete remission rate (CR) [ Time Frame: 1 year ]
    The proportion of patients with complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma

  3. Progression-free survival (PSF) [ Time Frame: 1 year ]
    Progression-free survival (PFS) is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause

  4. Overall survival (OS) [ Time Frame: 1 year ]
    Overall survival (OS) is defined as the time from start of study treatment to date of death due to any cause.

  5. Adverse Events [ Time Frame: 1 year ]
    Type, incidence, severity, seriousness, and relatedness of adverse events, and laboratory abnormalities


Other Outcome Measures:
  1. Event-Free survival (EFS) [ Time Frame: 1 year ]
    Event-free survival (EFS) is defined as the time from start of study treatment to any treatment failure including disease progression, or discontinuation of treatment for any reason

  2. B symptom resolution rate [ Time Frame: 1 year ]
    B symptom resolution rate is defined as the proportion of patients with lymphoma-related B symptoms at baseline who achieve resolution of all B symptoms at any time during the treatment period.

  3. CD30 expression [ Time Frame: 1 year ]
    Correlation between CD30 expression and response



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent.
  • Males and females ≥18 and ≤75 years at the time of enrolment.
  • Histologically confirmed diagnosis of PTCL (PTCL-not otherwise specified [PTCL-NOS], angioimmunoblastic T cell lymphoma [AILT] and transformed mycosis fungoides) according to World Health Organization (2008) classification.
  • Histologically confirmed CD30+ PTCL.
  • Availability of histological material for central review and pathobiological studies.
  • Failed at least one prior systemic antilymphoma therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1 at study entry.
  • At least one site of disease measurable in two dimensions by computed tomography. Both nodal and extranodal disease will be considered (lymphnodes must have long axis of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 cm and short axis >1.0 cm).
  • Hematology values within the following limits:

    • Absolute neutrophil count (ANC) ≥ 1500/mm3 independent of growth factor support.
    • Platelets ≥75,000/mm3 or ≥50,000/mm3 if bone marrow involvement is independent of transfusion support.
    • Hemoglobin level ≥8 g/dL.
  • Biochemical values within the following limits:

    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN).
    • Total bilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin).
    • Serum creatinine ≤ 2 x ULN.
    • Serum albumin ≥ 3 g/dL.
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication.
  • WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method or practice true abstinence from sexual intercourse during the study and for 6 months after the last dose of study drug.
  • Male subjects and their female partners of childbearing potential must be willing to use an appropriate method of contraception or practice true abstinence from sexual intercourse during the study and for 6 months after the last dose of study drug.

Exclusion Criteria:

  • Diagnosis of CTCL, ALCL, mycosis fungoides or Sezary Syndrome.
  • CD30 expression < 10 %.
  • Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives of last dose of that prior treatment.
  • Patients underwent major surgery without complete recovery
  • Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
  • Any serious active disease or co-morbid medical condition (according to investigator's decision).
  • Prior history of malignancies other than lymphoma (except for a history of a complete resection for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years.
  • Patients with peripheral neuropathy of grade 3-4 (also grade 2 with persistent pain, unresponsive to treatment).
  • Signs or symptoms of progressive multifocal leukoencephalopathy (PML).
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study.
  • CNS disease (meningeal and/or brain involvement by lymphoma) or testicular involvement.
  • History of clinically relevant liver or renal insufficiency; significant cardiac, vascular pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances.
  • Known history of any of the following cardiovascular conditions:

    • Myocardial infarction within 2 years from enrollment
    • New York Heart Association (NYHA) Class III or IV heart failure
    • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    • Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50%
  • Active opportunistic infection.
  • Known history of Human Immunodeficiency Virus (HIV) or Hepatitis C or active infection with Hepatitis B.
  • Prior allogeneic stem cell transplant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02497131


Contacts
Layout table for location contacts
Contact: Uffici Studi FIL 00390131206288 segreteria@filinf.it

Locations
Layout table for location information
Italy
Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi Recruiting
Bologna, Italy, 40138
Contact: Vittorio Stefoni, MD    +39.0516363680    vittorio.stefoni2@unibo.it   
A.O.Spedali civili di Brescia Not yet recruiting
Brescia, Italy
Principal Investigator: Giuseppe Rossi, MD         
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori Recruiting
Milano, Italy
Principal Investigator: Paolo Corradini, MD         
SC Ematologia - Città della Salute e della Scienza Recruiting
Torino, Italy, 10126
Principal Investigator: Umberto Vitolo, MD         
A.O. Universitaria S. Maria Della Misericordia Di Udine Recruiting
Udine, Italy, 33100
Principal Investigator: Stefano Volpetti, MD         
Sponsors and Collaborators
Fondazione Italiana Linfomi ONLUS
Investigators
Layout table for investigator information
Principal Investigator: Vittorio Stefoni, MD Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi

Layout table for additonal information
Responsible Party: Fondazione Italiana Linfomi ONLUS
ClinicalTrials.gov Identifier: NCT02497131    
Other Study ID Numbers: FIL_PTCL_BV
First Posted: July 14, 2015    Key Record Dates
Last Update Posted: February 10, 2020
Last Verified: September 2019
Keywords provided by Fondazione Italiana Linfomi ONLUS:
PTCL
CD30+
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphatic Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs